{"title":"White Light","description":"\u003cstyle\u003e\n  .brand-page { max-width: 900px; margin: 0 auto; padding: 20px; font-family: sans-serif; }\n  .brand-hero { text-align: center; padding: 40px 20px; background: #f8f8f8; border-radius: 10px; margin-bottom: 30px; }\n  .brand-hero h2 { font-size: 2.2em; margin-bottom: 10px; }\n  .brand-intro { font-size: 1.05em; line-height: 1.7; margin-bottom: 30px; }\n  .brand-cards { display: grid; grid-template-columns: repeat(3, 1fr); gap: 20px; margin-bottom: 30px; }\n  .brand-card { border: 1px solid #e0e0e0; border-radius: 8px; padding: 20px; background: #fff; }\n  .brand-card h4 { margin-top: 0; font-size: 1.05em; }\n  .brand-why ul { padding-left: 20px; line-height: 1.8; }\n  .brand-faq { margin-bottom: 30px; }\n  .brand-faq details { border: 1px solid #e0e0e0; border-radius: 6px; padding: 12px 16px; margin-bottom: 10px; }\n  .brand-faq summary { font-weight: 600; cursor: pointer; }\n  .faq-answer { margin-top: 10px; line-height: 1.7; color: #555; }\n  .brand-cta { text-align: center; margin: 30px 0; }\n  .brand-cta a { background: #333; color: #fff; padding: 14px 30px; border-radius: 6px; text-decoration: none; font-weight: 600; }\n  .brand-links { text-align: center; color: #666; font-size: 0.95em; }\n  .brand-links a { color: #333; }\n  @media (max-width: 768px) { .brand-cards { grid-template-columns: repeat(2, 1fr); } }\n  @media (max-width: 480px) { .brand-cards { grid-template-columns: 1fr; } }\n\u003c\/style\u003e\n\n\u003cdiv class=\"brand-page\"\u003e\n  \u003cdiv class=\"brand-hero\"\u003e\n    \u003ch2\u003eWhite Light\u003c\/h2\u003e\n    \u003cp class=\"tagline\"\u003e\u003cem\u003ePrecision Research Compounds for the Modern Laboratory\u003c\/em\u003e\u003c\/p\u003e\n  \u003c\/div\u003e\n\n  \u003cp class=\"brand-intro\"\u003e\u003cstrong\u003eWhite Light\u003c\/strong\u003e specializes in high-purity research chemicals for scientific investigation. Their flagship compound, SR-17018, was first described by researchers at the Scripps Research Institute in 2017 and represents a significant tool compound in mu-opioid receptor pharmacology — a G-protein-biased partial agonist with an 80–100 fold selectivity for G-protein signaling over β-arrestin2 recruitment, the pathway associated with classical opioid side effects.\u003c\/p\u003e\n\n  \u003cdiv class=\"brand-cards\"\u003e\n    \u003cdiv class=\"brand-card\"\u003e\n      \u003ch4\u003eSR-17018 Tablets\u003c\/h4\u003e\n      \u003cp\u003eG-protein-biased partial MOR agonist (Kᵢ 11 nM) in a convenient 10-count tablet format. 69% oral bioavailability and efficient CNS penetration support flexible study designs.\u003c\/p\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"brand-card\"\u003e\n      \u003ch4\u003eBiased Ligand Profile\u003c\/h4\u003e\n      \u003cp\u003e80–100 fold bias factor for G-protein signaling over β-arrestin2 relative to DAMGO. Near-irreversible MOR binding, yet fully reversible by naloxone — consistent with allosteric site interaction.\u003c\/p\u003e\n    \u003c\/div\u003e\n    \u003cdiv class=\"brand-card\"\u003e\n      \u003ch4\u003eResearch-Grade Quality\u003c\/h4\u003e\n      \u003cp\u003eManufactured under controlled conditions with batch-to-batch consistency. Molecular formula C₁₉H₁₈Cl₃N₃O, molar mass 410.72 g·mol⁻¹, log P 4.75.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"brand-why\"\u003e\n    \u003ch3\u003eWhy Choose White Light?\u003c\/h3\u003e\n    \u003cul\u003e\n      \u003cli\u003e\n\u003cstrong\u003eScripps Research Pedigree\u003c\/strong\u003e — SR-17018 was developed and first published by Laura Bohn and colleagues at the Scripps Research Institute, with the patent filed in 2016.\u003c\/li\u003e\n      \u003cli\u003e\n\u003cstrong\u003eHigh Oral Bioavailability\u003c\/strong\u003e — 69% oral bioavailability with an approximately 6-hour elimination half-life, simplifying pharmacokinetic study designs.\u003c\/li\u003e\n      \u003cli\u003e\n\u003cstrong\u003eDefined Receptor Selectivity\u003c\/strong\u003e — Strong MOR selectivity (Kᵢ 11 nM) with minimal delta-opioid receptor activity (Kᵢ \u0026gt;10,000 nM), supporting clean mechanistic studies.\u003c\/li\u003e\n      \u003cli\u003e\n\u003cstrong\u003eAtypical Tolerance Profile\u003c\/strong\u003e — Studied for its reduced tolerance development and withdrawal intensity relative to classical MOR agonists — a key area of opioid dependence research.\u003c\/li\u003e\n    \u003c\/ul\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"brand-faq\"\u003e\n    \u003ch3\u003eFrequently Asked Questions\u003c\/h3\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003eWhat is SR-17018?\u003c\/summary\u003e\n      \u003cdiv class=\"faq-answer\"\u003eSR-17018 (C₁₉H₁₈Cl₃N₃O) is a synthetic piperidinylbenzimidazolone compound and G-protein-biased partial agonist at the mu-opioid receptor. It was first described in the scientific literature in 2017 by researchers at the Scripps Research Institute and is used as a pharmacological tool compound for studying biased opioid signaling.\u003c\/div\u003e\n    \u003c\/details\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003eWhat makes SR-17018 pharmacologically distinct?\u003c\/summary\u003e\n      \u003cdiv class=\"faq-answer\"\u003eSR-17018 shows an 80–100 fold bias for G-protein activation over β-arrestin2 recruitment at the MOR, relative to DAMGO. It also exhibits non-competitive, near-irreversible receptor binding that is nevertheless fully reversed by naloxone, a profile not seen in classical orthosteric opioid agonists.\u003c\/div\u003e\n    \u003c\/details\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003eIs SR-17018 approved for human use?\u003c\/summary\u003e\n      \u003cdiv class=\"faq-answer\"\u003eNo. SR-17018 is a research chemical that has only been assessed in preclinical research. It has not been formally studied in humans, is not FDA-approved, and its safety profile in humans is unknown. It is sold strictly for laboratory research purposes.\u003c\/div\u003e\n    \u003c\/details\u003e\n    \u003cdetails\u003e\n      \u003csummary\u003eWhat research areas is SR-17018 relevant to?\u003c\/summary\u003e\n      \u003cdiv class=\"faq-answer\"\u003eSR-17018 is relevant to opioid receptor pharmacology, biased agonism research, tolerance and dependence mechanisms, safety pharmacology (particularly respiratory depression profiling), and opioid discontinuation\/withdrawal research across multiple opioid classes.\u003c\/div\u003e\n    \u003c\/details\u003e\n  \u003c\/div\u003e\n\n  \u003cdiv class=\"brand-cta\"\u003e\n    \u003ca href=\"#collection-product-grid\"\u003eShop White Light Products\u003c\/a\u003e\n  \u003c\/div\u003e\n\n  \u003cp class=\"brand-links\"\u003e\n    Explore related collections: \u003ca href=\"\/collections\/research-chemicals\"\u003eResearch Chemicals\u003c\/a\u003e  | \n    \u003ca href=\"\/collections\/all-brands\"\u003eAll Brands\u003c\/a\u003e\n  \u003c\/p\u003e\n\u003c\/div\u003e\n","products":[{"product_id":"white-light-sr-17-tablets-10ct","title":"White Light - SR-17 Tablets [10ct]","description":"\u003cp\u003e\u003cstrong\u003eWhite Light SR-17\u003c\/strong\u003e is a synthetic G-protein-biased partial agonist of the mu-opioid receptor (MOR), first described by Laura Bohn and colleagues at the Scripps Research Institute in 2017 and patented in 2016. It represents a distinct class of opioid receptor ligands developed to probe the functional consequences of biased MOR signaling.\u003c\/p\u003e\n\n\u003ch3\u003eMechanism of Action\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eG-Protein Biased Agonism\u003c\/strong\u003e — SR-17018 demonstrates strong selectivity for G-protein signaling over β-arrestin2 recruitment at the MOR, with an 80–100 fold bias factor relative to the reference agonist DAMGO.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNon-Competitive Binding Profile\u003c\/strong\u003e — Exhibits non-competitive MOR agonism with nearly irreversible receptor binding characteristics, yet remains fully reversible by antagonists such as naloxone — suggesting allosteric site interaction rather than classical orthosteric binding.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePartial Agonist Efficacy\u003c\/strong\u003e — GTPγS binding: 72–75% efficacy (EC₅₀ 97–193 nM); cAMP accumulation: 105% efficacy (EC₅₀ 76 nM); β-arrestin2 recruitment: ≤10% efficacy (EC₅₀ \u0026gt;10,000 nM).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eReceptor Binding Profile\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMOR Affinity (Kᵢ):\u003c\/strong\u003e 11 nM — high affinity, primary target\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKOR Affinity (Kᵢ):\u003c\/strong\u003e 68 nM — moderate kappa-opioid receptor activity\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDOR Affinity (Kᵢ):\u003c\/strong\u003e \u0026gt;10,000 nM — essentially no delta-opioid receptor activity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003ePharmacokinetics\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOral Bioavailability:\u003c\/strong\u003e 69% — suitable for oral dosing study designs\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCNS Penetration:\u003c\/strong\u003e Efficiently crosses the blood–brain barrier\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eElimination Half-Life:\u003c\/strong\u003e Approximately 6 hours\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLipophilicity:\u003c\/strong\u003e log P = 4.75 (highly lipophilic)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDuration:\u003c\/strong\u003e Longer duration of action than morphine or fentanyl at equivalent doses\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eChemical Data\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMolecular Formula:\u003c\/strong\u003e C₁₉H₁₈Cl₃N₃O\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMolar Mass:\u003c\/strong\u003e 410.72 g·mol⁻¹\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eClass:\u003c\/strong\u003e Piperidinylbenzimidazolone (piperidine-benzimidazole derivative)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e 10ct tablets\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eResearch Context\u003c\/h3\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTolerance \u0026amp; Withdrawal Research\u003c\/strong\u003e — SR-17018 is studied for its atypical tolerance profile and reduced withdrawal symptom intensity relative to conventional MOR agonists, making it a useful tool compound in opioid dependence research.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eOpioid Discontinuation Studies\u003c\/strong\u003e — Investigated as a research tool for understanding opioid tolerance reversal and the pharmacological basis of withdrawal management across opioid classes including fentanyl, heroin, methadone, and buprenorphine.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSafety Pharmacology\u003c\/strong\u003e — Studied for its favorable therapeutic window profile relative to classical opioids, particularly regarding respiratory depression parameters.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eQuality Assurance\u003c\/h3\u003e\n\u003cp\u003eWhite Light research compounds are manufactured under controlled conditions to ensure consistent compound integrity and batch-to-batch reproducibility for reliable research outcomes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cem\u003e\u003cstrong\u003e⚠ FOR LABORATORY RESEARCH USE ONLY. Not for human consumption. Not FDA-approved. Not a dietary supplement. SR-17018 has not been formally studied in humans and its safety profile in humans is unknown. Handle only by trained research personnel in accordance with applicable institutional protocols.\u003c\/strong\u003e\u003c\/em\u003e\u003c\/p\u003e\n","brand":"White Light","offers":[{"title":"Default Title","offer_id":52474982039733,"sku":null,"price":34.5,"currency_code":"USD","in_stock":false}]}],"url":"https:\/\/smokeshopdaddy.com\/collections\/white-light.oembed","provider":"BLACKMARKET GROUP LLC","version":"1.0","type":"link"}